NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Simple item page
dc.citation.issue1
dc.citation.volume16
dc.contributor.authorEFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel)
dc.contributor.authorTurck D
dc.contributor.authorBresson J-L
dc.contributor.authorBurlingame B
dc.contributor.authorDean T
dc.contributor.authorFairweather-Tait S
dc.contributor.authorHeinonen M
dc.contributor.authorHirsch-Ernst KI
dc.contributor.authorMangelsdorf I
dc.contributor.authorMcArdle HJ
dc.contributor.authorNaska A
dc.contributor.authorNeuhäuser-Berthold M
dc.contributor.authorNowicka G
dc.contributor.authorPentieva K
dc.contributor.authorSanz Y
dc.contributor.authorSjödin A
dc.contributor.authorStern M
dc.contributor.authorTomé D
dc.contributor.authorVan Loveren H
dc.contributor.authorVinceti M
dc.contributor.authorWillatts P
dc.contributor.authorMartin A
dc.contributor.authorStrain SJJ
dc.contributor.authorSiani A
dc.coverage.spatialUnited States
dc.date.accessioned2023-07-12T02:52:23Z
dc.date.accessioned2023-09-04T01:40:36Z
dc.date.available2017-12-13
dc.date.available2023-07-12T02:52:23Z
dc.date.available2023-09-04T01:40:36Z
dc.date.issued2018-01-18
dc.date.updated2023-07-10T02:03:28Z
dc.description.abstractFollowing an application from Newtricious R&D B.V., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to NWT-02 and a reduction of the loss of vision. The food proposed by the applicant as the subject of the health claim is NWT-02. NWT-02 is standardised by its content in lutein (≥ 1.10 mg), zeaxanthin (≥ 0.20 mg) and docosahexaenoic acid (DHA) (≥ 170 mg). The Panel considers that the food/constituent that is the subject of the health claim, NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, is sufficiently characterised. The claimed effect proposed by the applicant is 'reduces loss of vision'. The target population proposed by the applicant is 'healthy adults over 50 years of age'. The Panel considers that a reduction of the loss of vision is a beneficial physiological effect. The applicant provided two human intervention studies for the scientific substantiation of the claim. The Panel considers that the only study from which conclusions can be drawn for the scientific substantiation of the claim did not show an effect of NWT-02 on vision. The Panel concludes that a cause and effect relationship has not been established between the consumption of NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, and a reduction of the loss of vision.
dc.description.confidentialfalse
dc.edition.editionJanuary 2018
dc.format.extente05139-
dc.identifierARTN 5139
dc.identifierEFS25139
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/32625685
dc.identifier.citationEFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel) , Turck D, Bresson J-L, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhäuser-Berthold M, Nowicka G, Pentieva K, Sanz Y, Sjödin A, Stern M, Tomé D, Van Loveren H, Vinceti M, Willatts P, Martin A, Strain SJJ, Siani A. (2018). NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.. EFSA J. 16. 1. (pp. e05139-).
dc.identifier.doi10.2903/j.efsa.2018.5139
dc.identifier.eissn1831-4732
dc.identifier.elements-typejournal-article
dc.identifier.harvestedMassey_Dark
dc.identifier.issn1831-4732
dc.identifier.urihttp://hdl.handle.net/10179/19855
dc.languageeng
dc.publisherJohn Wiley and Sons Ltd on behalf of European Food Safety Authority
dc.publisher.urihttps://efsa.onlinelibrary.wiley.com/doi/full/10.2903/j.efsa.2018.5139
dc.relation.isPartOfEFSA J
dc.rightsCC BY-ND 4.0
dc.rights.urihttps://creativecommons.org/licenses/by-nd/4.0/
dc.subjectNWT‐02
dc.subjecthealth claim
dc.subjectvision
dc.subjectvision acuity
dc.titleNWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
dc.typeJournal article
pubs.elements-id444546
pubs.organisational-groupOther
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
444546 PDF.pdf
Size:
749.21 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles